Physician profile

Mukesh Sharma

Gastroenterology (Internal Medicine) · Plano, TX

NPI 1922501519

$1,677.68

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$654.72

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,102.56 2022-2024 Rinvoq, Skyrizi
Boston Scientific Corporation $134.53 2021-2024 Apollo Esg System
Intercept Pharmaceuticals, INC. $116.65 2021
Takeda Pharmaceuticals U.S.A., INC. $103.05 2021-2023 Gattex
Novo Nordisk INC $97.47 2022
Gilead Sciences, INC. $55.21 2021-2024 Epclusa
Glaxosmithkline, LLC. $19.98 2020
Pfizer INC. $18.73 2024
Amgen INC. $15.81 2020
Astrazeneca Pharmaceuticals LP $13.69 2024 Lokelma

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mukesh Sharma

$1,677.68

in general payments reported 2019-2025

Years
2020-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/8800928/mukesh-sharma

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.